Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LDHA | P00338 | 1/20 | 0.44 |
| ▸ | SRR | Q9GZT4 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.36 |
| ▸ | FOLH1 | Q04609 | 5/20 | 0.36 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.31 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.31 |
| ▸ | TET2 | Q6N021 | 3/20 | 0.31 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.31 |
| ▸ | KDM4A | O75164 | 2/20 | 0.31 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.31 |
| ▸ | KDM2A | Q9Y2K7 | 2/20 | 0.31 |
| ▸ | TET3 | O43151 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Malonic Acid SCHEMBL2554958 | 0.97 | LDHA (0.50) | LDHASRRTDP1SMN1; SMN2SLC22A6 | |
| SCHEMBL27782115 | 0.81 | TDP1 (0.42) | TDP1SMN1; SMN2SLC22A6 | |
| SCHEMBL11762118 | 0.79 | LDHA (0.47) | LDHASRRTDP1SMN1; SMN2SLC22A6 | |
| SCHEMBL9005314 | 0.78 | SMN1; SMN2 (0.62) | LDHASRRTDP1SMN1; SMN2SLC22A6 | |
| SCHEMBL4669647 | 0.78 | SMN1; SMN2 (0.62) | LDHASRRTDP1SMN1; SMN2SLC22A6 | |
| SCHEMBL11403019 | 0.78 | HDAC1 (0.41) | TDP1SLC22A6FOLH1 | |
| SCHEMBL2491511 | 0.76 | GRIK1 (0.48) | — | |
| SCHEMBL16937252 | 0.74 | LDHA (0.42) | LDHASRRTDP1SMN1; SMN2SLC22A6 | |
| SCHEMBL17733 | 0.74 | ALDH1A1 (0.46) | LDHASRRTDP1SLC22A6 | |
| SCHEMBL786963 | 0.74 | CA2 (0.46) | LDHASRRTDP1FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113166380-B | RMA crosslinkable polymers | 欧尼克斯荷兰有限公司 | 2023-04-25 | — | — | CN | disclosed |
| EP-3891206-A1 | RMA CROSSLINKABLE POLYMER | Allnex Netherlands B.V. (NL) | 2021-10-13 | — | — | EP | disclosed |
| CN-113166380-A | RMA crosslinkable polymers | 欧尼克斯荷兰有限公司 | 2021-07-23 | — | — | CN | disclosed |
| EP-3257890-B1 | CROSSLINKABLE COMPOSITION | ALLNEX NETHERLANDS BV (NL) | 2021-06-02 | — | — | EP | disclosed |
| WO-2020115153-A1 | RMA CROSSLINKABLE POLYMER | ALLNEX NETHERLANDS B.V. (NL) | 2020-06-11 | — | — | WO | disclosed |
| EP-3663326-A1 | RMA CROSSLINKABLE POLYMER | Allnex Netherlands B.V. (NL) | 2020-06-10 | — | — | EP | disclosed |
| EP-3257890-A1 | CROSSLINKABLE COMPOSITION | Allnex Netherlands B.V. (NL) | 2017-12-20 | — | — | EP | disclosed |
| EP-2985308-B1 | CROSSLINKABLE COMPOSITION | ALLNEX NETHERLANDS BV (NL) | 2017-07-19 | — | — | EP | disclosed |
| US-9534081-B2 | Crosslinkable composition crosslinkable with a latent base catalyst | NUPLEX RESINS B.V. (NL) | 2017-01-03 | — | — | US | disclosed |
| EP-2556106-B1 | CROSSLINKABLE COMPOSITION CROSSLINKABLE WITH A LATENT BASE CATALYST | NUPLEX RESINS BV (NL) | 2016-08-10 | — | — | EP | disclosed |
| EP-2556108-B1 | CROSSLINKABLE COMPOSITION CROSSLINKABLE WITH A LATENT BASE CATALYST | NUPLEX RESINS BV (NL) | 2014-07-09 | — | — | EP | disclosed |
| EP-2556107-B1 | CROSSLINKABLE COMPOSITION CROSSLINKABLE WITH A LATENT BASE CATALYST | NUPLEX RESINS BV (NL) | 2014-07-09 | — | — | EP | disclosed |
| US-20130210986-A1 | CROSSLINKABLE COMPOSITION CROSSLINKABLE WITH A LATENT BASE CATALYST | NUPLEX RESINS B.V. (NL) | 2013-08-15 | — | — | US | disclosed |
| US-20130053505-A1 | CROSSLINKABLE COMPOSITION CROSSLINKABLE WITH A LATENT BASE CATALYST | NUPLEX RESINS B.V. (NL) | 2013-02-28 | — | — | US | disclosed |
| US-20130041091-A1 | CROSSLINKABLE COMPOSITION CROSSLINKABLE WITH A LATENT BASE CATALYST | NUPLEX RESINS B.V. (NL) | 2013-02-14 | — | — | US | disclosed |
| EP-2556107-A1 | CROSSLINKABLE COMPOSITION CROSSLINKABLE WITH A LATENT BASE CATALYST | Nuplex Resins B.V. (NL) | 2013-02-13 | — | — | EP | disclosed |
| EP-2556108-A1 | CROSSLINKABLE COMPOSITION CROSSLINKABLE WITH A LATENT BASE CATALYST | Nuplex Resins B.V. (NL) | 2013-02-13 | — | — | EP | disclosed |
| WO-2011124663-A1 | CROSSLINKABLE COMPOSITION CROSSLINKABLE WITH A LATENT BASE CATALYST | NUPLEX RESINS B.V. (NL) | 2011-10-13 | — | — | WO | disclosed |
| WO-2011124665-A1 | CROSSLINKABLE COMPOSITION CROSSLINKABLE WITH A LATENT BASE CATALYST | NUPLEX RESINS B.V. (NL) | 2011-10-13 | — | — | WO | disclosed |
| EP-2374836-A1 | Crosslinkable composition crosslinkable with a latent base catalyst. | Nuplex Resins B.V. (NL) | 2011-10-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130041091-A1 | CROSSLINKABLE COMPOSITION CROSSLINKABLE WITH A LATENT BASE CATALYST | ARL1, ASH2L, COL1A1 | LDHA 655/4885SRR 1912/4885TDP1 804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.